<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Biomarkers for liver failure</title>

<script src="site_libs/header-attrs-2.11/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<script src="site_libs/htmlwidgets-1.5.4/htmlwidgets.js"></script>
<link href="site_libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="site_libs/datatables-binding-0.19/datatables.js"></script>
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="site_libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="site_libs/nouislider-7.0.10/jquery.nouislider.min.css" rel="stylesheet" />
<script src="site_libs/nouislider-7.0.10/jquery.nouislider.min.js"></script>
<link href="site_libs/selectize-0.12.0/selectize.bootstrap3.css" rel="stylesheet" />
<script src="site_libs/selectize-0.12.0/selectize.min.js"></script>
<link href="site_libs/crosstalk-1.1.1/css/crosstalk.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.1.1/js/crosstalk.min.js"></script>
<link href="site_libs/ionicons-2.0.1/css/ionicons.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>





<link rel="stylesheet" href="custom-css.css" type="text/css" />



<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.tab('show');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Biomarkers of Clinical Trials</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">Home</a>
</li>
<li>
  <a href="Biomarkers.html">Biomarkers</a>
</li>
<li>
  <a href="Conditions.html">Conditions</a>
</li>
<li>
  <a href="Pairs.html">Top Pairs</a>
</li>
<li>
  <a href="Liver.html">Liver Failure</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://github.com">
    <span class="ion ion-social-github"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Biomarkers for liver failure</h1>

</div>


<div id="htmlwidget-d8ab16059b00067c9798" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-d8ab16059b00067c9798">{"x":{"filter":"top","vertical":false,"filterHTML":"<tr>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"character\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n  <\/td>\n  <td data-type=\"integer\" style=\"vertical-align: top;\">\n    <div class=\"form-group has-feedback\" style=\"margin-bottom: auto;\">\n      <input type=\"search\" placeholder=\"All\" class=\"form-control\" style=\"width: 100%;\"/>\n      <span class=\"glyphicon glyphicon-remove-circle form-control-feedback\"><\/span>\n    <\/div>\n    <div style=\"display: none;position: absolute;width: 200px;opacity: 1\">\n      <div data-min=\"2005\" data-max=\"2021\"><\/div>\n      <span style=\"float: left;\"><\/span>\n      <span style=\"float: right;\"><\/span>\n    <\/div>\n  <\/td>\n<\/tr>","caption":"<caption>Table 1:  Examples of biomarkers for Liver Failure<\/caption>","data":[["<a href='https://clinicaltrials.gov/ct2/show/NCT04906083' target='_blank'>NCT04906083<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04906083' target='_blank'>NCT04906083<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04906083' target='_blank'>NCT04906083<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04906083' target='_blank'>NCT04906083<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT05019352' target='_blank'>NCT05019352<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT05019352' target='_blank'>NCT05019352<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04906083' target='_blank'>NCT04906083<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04906083' target='_blank'>NCT04906083<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT05019352' target='_blank'>NCT05019352<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT05019352' target='_blank'>NCT05019352<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT05030571' target='_blank'>NCT05030571<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT05019352' target='_blank'>NCT05019352<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04447911' target='_blank'>NCT04447911<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04335058' target='_blank'>NCT04335058<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04335058' target='_blank'>NCT04335058<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04335058' target='_blank'>NCT04335058<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04335058' target='_blank'>NCT04335058<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04335058' target='_blank'>NCT04335058<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04335058' target='_blank'>NCT04335058<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04447911' target='_blank'>NCT04447911<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04474262' target='_blank'>NCT04474262<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03908255' target='_blank'>NCT03908255<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03908255' target='_blank'>NCT03908255<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03908255' target='_blank'>NCT03908255<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04195282' target='_blank'>NCT04195282<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04195282' target='_blank'>NCT04195282<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03791190' target='_blank'>NCT03791190<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03791190' target='_blank'>NCT03791190<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03908255' target='_blank'>NCT03908255<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03908255' target='_blank'>NCT03908255<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04195282' target='_blank'>NCT04195282<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04195282' target='_blank'>NCT04195282<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03863002' target='_blank'>NCT03863002<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04186572' target='_blank'>NCT04186572<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04186572' target='_blank'>NCT04186572<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04116242' target='_blank'>NCT04116242<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04116242' target='_blank'>NCT04116242<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04116242' target='_blank'>NCT04116242<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04116242' target='_blank'>NCT04116242<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04116242' target='_blank'>NCT04116242<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT04116242' target='_blank'>NCT04116242<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03860155' target='_blank'>NCT03860155<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03627013' target='_blank'>NCT03627013<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03640728' target='_blank'>NCT03640728<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03761238' target='_blank'>NCT03761238<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03761238' target='_blank'>NCT03761238<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03761238' target='_blank'>NCT03761238<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03761238' target='_blank'>NCT03761238<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03761238' target='_blank'>NCT03761238<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03761238' target='_blank'>NCT03761238<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03761238' target='_blank'>NCT03761238<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03773887' target='_blank'>NCT03773887<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03082885' target='_blank'>NCT03082885<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03082885' target='_blank'>NCT03082885<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03082885' target='_blank'>NCT03082885<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03082885' target='_blank'>NCT03082885<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03312036' target='_blank'>NCT03312036<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03312036' target='_blank'>NCT03312036<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03312036' target='_blank'>NCT03312036<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03065699' target='_blank'>NCT03065699<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT03216668' target='_blank'>NCT03216668<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02788240' target='_blank'>NCT02788240<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02788240' target='_blank'>NCT02788240<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02788240' target='_blank'>NCT02788240<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02788240' target='_blank'>NCT02788240<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02837939' target='_blank'>NCT02837939<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02837939' target='_blank'>NCT02837939<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02719210' target='_blank'>NCT02719210<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02719210' target='_blank'>NCT02719210<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02837939' target='_blank'>NCT02837939<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02857010' target='_blank'>NCT02857010<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02857010' target='_blank'>NCT02857010<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02857010' target='_blank'>NCT02857010<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02857010' target='_blank'>NCT02857010<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02719210' target='_blank'>NCT02719210<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02719210' target='_blank'>NCT02719210<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02719210' target='_blank'>NCT02719210<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02719210' target='_blank'>NCT02719210<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02837939' target='_blank'>NCT02837939<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02857010' target='_blank'>NCT02857010<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02857010' target='_blank'>NCT02857010<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02812121' target='_blank'>NCT02812121<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02375867' target='_blank'>NCT02375867<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02375867' target='_blank'>NCT02375867<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02557724' target='_blank'>NCT02557724<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02557724' target='_blank'>NCT02557724<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02557724' target='_blank'>NCT02557724<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02557724' target='_blank'>NCT02557724<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02557724' target='_blank'>NCT02557724<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02635347' target='_blank'>NCT02635347<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02635347' target='_blank'>NCT02635347<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02343016' target='_blank'>NCT02343016<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02467348' target='_blank'>NCT02467348<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02584283' target='_blank'>NCT02584283<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02183376' target='_blank'>NCT02183376<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02183376' target='_blank'>NCT02183376<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02183376' target='_blank'>NCT02183376<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02161224' target='_blank'>NCT02161224<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02161224' target='_blank'>NCT02161224<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02115321' target='_blank'>NCT02115321<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02170571' target='_blank'>NCT02170571<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02170571' target='_blank'>NCT02170571<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02090621' target='_blank'>NCT02090621<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02090621' target='_blank'>NCT02090621<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02090621' target='_blank'>NCT02090621<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02310542' target='_blank'>NCT02310542<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02259855' target='_blank'>NCT02259855<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT02161224' target='_blank'>NCT02161224<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01937130' target='_blank'>NCT01937130<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01937130' target='_blank'>NCT01937130<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01826760' target='_blank'>NCT01826760<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01826760' target='_blank'>NCT01826760<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01826760' target='_blank'>NCT01826760<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01937130' target='_blank'>NCT01937130<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01937130' target='_blank'>NCT01937130<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01937130' target='_blank'>NCT01937130<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01937130' target='_blank'>NCT01937130<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01724398' target='_blank'>NCT01724398<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01724398' target='_blank'>NCT01724398<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01724398' target='_blank'>NCT01724398<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01726465' target='_blank'>NCT01726465<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01726465' target='_blank'>NCT01726465<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01726465' target='_blank'>NCT01726465<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01726465' target='_blank'>NCT01726465<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01724398' target='_blank'>NCT01724398<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01724398' target='_blank'>NCT01724398<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01341951' target='_blank'>NCT01341951<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01383460' target='_blank'>NCT01383460<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01318525' target='_blank'>NCT01318525<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01429038' target='_blank'>NCT01429038<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01429038' target='_blank'>NCT01429038<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01201720' target='_blank'>NCT01201720<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01201720' target='_blank'>NCT01201720<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01201720' target='_blank'>NCT01201720<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01201720' target='_blank'>NCT01201720<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01201720' target='_blank'>NCT01201720<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01201720' target='_blank'>NCT01201720<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01218464' target='_blank'>NCT01218464<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01201720' target='_blank'>NCT01201720<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01013194' target='_blank'>NCT01013194<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01036932' target='_blank'>NCT01036932<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT01013194' target='_blank'>NCT01013194<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT00623662' target='_blank'>NCT00623662<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT00623662' target='_blank'>NCT00623662<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT00287235' target='_blank'>NCT00287235<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT00162552' target='_blank'>NCT00162552<\/a>","<a href='https://clinicaltrials.gov/ct2/show/NCT00162552' target='_blank'>NCT00162552<\/a>"],["ALB","ALB","F2","F2","GOT1","GOT2","GPT","GPT","IL6","IL6","ITGAM","SKAP2","AVP","HBA1","HBA1","HBA2","HBA2","HBB","HBB","REN","REN","AFP","AFP","ALB","ALB","ALB","ALB","ALB","ALB","ALB","ALB","CRP","CRP","CRP","F2","F2","GGT1","GOT1","GOT1","GOT2","GOT2","GPT","GPT","GPT","GPT","GPT","GPT","GPT","GPT","GPT","HBA1","HBA1","HBA1","HBA2","HBA2","HBA2","HBB","HBB","HBB","LCN2","LCN2","MERTK","MERTK","MERTK","MERTK","MERTK","MERTK","GGT2","GOT1","GOT2","GPT","GPT","HGF","IL1A","IL1B","IL6","IL6","IL6","IL6","CXCL8","IL10","KRT7","KRT18","TNF","TNF","TNF","TNF","TNFRSF12A","ALB","ALB","ALB","ALB","ALB","CRP","GGT1","GGT1","GGT1","GGT1","GGT1","GGT1","GGT1","GOT1","GOT1","GOT1","GOT1","GOT1","GOT1","GOT1","GOT2","GOT2","GOT2","GOT2","GOT2","GOT2","GOT2","GPT","GPT","HBA1","HBA2","HBB","IL1RN","IL6","CXCL8","IL10","LCN2","LCN2","TNF","GGT2","GGT2","GGT2","GGT2","GGT2","GGT2","GGT2","ALB","FASLG","CD34","CD34","CD34","CD34","CD79A","GOT1","GOT2","IGHE","IL6","IL6","IL6","KIR2DL1","KIR2DL3","KIR3DL1","KLRC1","LCN2","LCN2","LCN2","LCN2","PRF1","TNF","TNF","TNF","TNF","TNF","VWF","VWF","NCR1","KLRK1","F2","F2","F2","GOT1","GOT1","GOT2","GOT2","GPT","GPT","GPT","GPT","GPT","GPT","GPT","GPT","GPT","HMGB1","HMGB1","LCN2","REN","THBD","CYCS","ALB","ALB","ALB","ALB","ALB","ALB","DPP4","DPP4","DPP4","EPO","EPO","F2","F2","F2","F3","F3","HBA1","HBA1","HBA2","HBA2","HBB","HBB","IFNA1","EPX","CASP3","CASP3","HBA1","HBA2","HBB","KRT18","KRT18","KRT18","KRT18","ALB","ALB","F2","GOT1","GOT1","GOT2","GOT2","GPT","GPT","CD34","CD34","F2","GGT1","GGT2","AFP","AFP","ALB","ALB","ALB","ALB","ALB","BCHE","BCHE","F2","F2","GPT","GPT","GPT","REN","ALB","CD34","F2","ALB","TTR","F2","IL6","TNF"],["protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","expression","protein","protein","biomarker","biomarker","biomarker","biomarker","biomarker","biomarker","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","biomarker","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","biomarker","biomarker","biomarker","biomarker","protein","protein","protein","biomarker","biomarker","biomarker","biomarker","protein","protein","protein","biomarker","biomarker","biomarker","biomarker","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","biomarker","biomarker","biomarker","biomarker","protein","protein","protein","protein","protein","cell_surface","cell_surface","cell_surface","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","biomarker","protein","biomarker","protein","protein","protein","protein","protein","protein","protein","protein","biomarker","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","biomarker","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","cell_surface","protein","biomarker","biomarker","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein","protein"],["Changes in <span class='gene'>albumin<\/span> level refers to the changes of albumin at 24 week compared to baseline between the Intervention group and Control group.","Changes in <span class='gene'>albumin<\/span> level","Changes in <span class='gene'>prothrombin<\/span> time level refers to the changes of prothrombin time at 24 week compared to baseline between the Intervention group and Control group.","Changes in <span class='gene'>prothrombin<\/span> time level","Quick/INR, <span class='gene'>AST<\/span>, ALT, AP, g-GT","Quick/INR, <span class='gene'>AST<\/span>, ALT, AP, g-GT","Changes in <span class='gene'>alanine aminotransferase<\/span> level refers to the changes of alanine aminotransferase at 24 week compared to baseline between the Intervention group and Control group.","Changes in <span class='gene'>alanine aminotransferase<\/span> level","<span class='gene'>Interleukin-6<\/span> after 72 hours","<span class='gene'>Interleukin-6<\/span>","<span class='gene'>CD11b<\/span> expression","<span class='gene'>SAPS<\/span> II","Change in plasma <span class='gene'>copeptin<\/span>","Number of participants achieving <span class='gene'>hemoglobin<\/span> level > 12 g/dl","Number of participants achieving <span class='gene'>hemoglobin<\/span> level > 12 g/dl iron deficiency anemia in patients with Chronic Liver Disease of any etiology.","Number of participants achieving <span class='gene'>hemoglobin<\/span> level > 12 g/dl","Number of participants achieving <span class='gene'>hemoglobin<\/span> level > 12 g/dl iron deficiency anemia in patients with Chronic Liver Disease of any etiology.","Number of participants achieving <span class='gene'>hemoglobin<\/span> level > 12 g/dl","Number of participants achieving <span class='gene'>hemoglobin<\/span> level > 12 g/dl iron deficiency anemia in patients with Chronic Liver Disease of any etiology.","Change in plasma <span class='gene'>renin<\/span>","Change in plasma <span class='gene'>renin<\/span> activity in both groups","Change of alpha fetoprotein (<span class='gene'>AFP<\/span>) level as a marker of liver function","Change of <span class='gene'>alpha fetoprotein<\/span> (AFP) level as a marker of liver function","Liver Function Test (ALT, AST, AP, <span class='gene'>Albumin<\/span>, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24","The clinical chemistry values for sodium, potassium, calcium, urea, creatinine, <span class='gene'>albumin<\/span>, total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma glytamyl transferase, alkaline phosphatase, CRP will be measured.","The following laboratory variables will be measured and evaluated: <span class='gene'>Albumin<\/span>, total bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (AP).","Change of <span class='gene'>albumin<\/span> (ALB) level as a maker of liver function","Change of <span class='gene'>ALB<\/span>umin (ALB) level as a maker of liver function","The Child Pugh Score, used to measure overall liver health and prognosis of liver disease, will be calculated (after each lab measurement and clinical assessment using <span class='gene'>serum albumin<\/span>, bilirubin, international normalized ratio, presence and severity of ascites and presence and severity of hepatic encephalopathy will be assessed using a numeric score assigned to each category. Total scores are a sum of each category and a higher total is associated with a worse prognosis. No subclassifications will be applied. Please see the reference section for a clinical application of this scale.","<span class='gene'>Albumin<\/span>","<span class='gene'>Serum albumin<\/span> measurement in grams per deciliter","Change of levels of <span class='gene'>C-reactive protein<\/span> in serum at Weeks 3, 4, 8, 12, 16, 20 and 24","The clinical chemistry values for sodium, potassium, calcium, urea, creatinine, albumin, total bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma glytamyl transferase, alkaline phosphatase, <span class='gene'>CRP<\/span> will be measured.","<span class='gene'>C-reactive protein<\/span> levels in the serum will be measured.","<span class='gene'>Prothrombin<\/span> time","<span class='gene'>Prothrombin<\/span> time is observed in the follow-up.","Liver Function Test (ALT, AST, AP, Albumin, Bilirubin, <span class='gene'>GGT<\/span>) at Weeks 3, 4, 8, 12, 16, 20 and 24","Serum <span class='gene'>AST<\/span> level","Liver Function Test (ALT, <span class='gene'>AST<\/span>, AP, Albumin, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24","Serum <span class='gene'>AST<\/span> level","Liver Function Test (ALT, <span class='gene'>AST<\/span>, AP, Albumin, Bilirubin, GGT) at Weeks 3, 4, 8, 12, 16, 20 and 24","The clinical chemistry values for sodium, potassium, calcium, urea, creatinine, albumin, total bilirubin, <span class='gene'>alanine aminotransferase<\/span>, aspartate aminotransferase, gamma glytamyl transferase, alkaline phosphatase, CRP will be measured.","The following laboratory variables will be measured and evaluated: Albumin, total bilirubin, alanine aminotransferase (<span class='gene'>ALT<\/span>), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (AP).","The following laboratory variables will be measured and evaluated: Albumin, total bilirubin, <span class='gene'>alanine aminotransferase<\/span> (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), alkaline phosphatase (AP).","Change of alanine aminotransferase (<span class='gene'>ALT<\/span>) level as a marker of liver function","Change of <span class='gene'>alanine aminotransferase<\/span> (ALT) level as a marker of liver function","Serum <span class='gene'>alanine aminotransferase<\/span> in units per liter","<span class='gene'>Alanine aminotransferase<\/span>","<span class='gene'>Alanine transaminase<\/span> is observed in the follow-up.","<span class='gene'>Alanine transaminase<\/span>","The hematological laboratory values for <span class='gene'>hemoglobin<\/span>, hematocrit, red blood cell count, white blood cell count with differential, platelet count will be measured.","<span class='gene'>hemoglobin<\/span>","Change of <span class='gene'>hemoglobin<\/span> level","The hematological laboratory values for <span class='gene'>hemoglobin<\/span>, hematocrit, red blood cell count, white blood cell count with differential, platelet count will be measured.","<span class='gene'>hemoglobin<\/span>","Change of <span class='gene'>hemoglobin<\/span> level","The hematological laboratory values for <span class='gene'>hemoglobin<\/span>, hematocrit, red blood cell count, white blood cell count with differential, platelet count will be measured.","<span class='gene'>hemoglobin<\/span>","Change of <span class='gene'>hemoglobin<\/span> level","Correlate the level of <span class='gene'>NGAL<\/span> with the development of ACLF and its severity evaluated by the CLIF-C ACLF score.","The level of <span class='gene'>NGAL<\/span> in plasma and urine will be determined routinely at the time of diagnosis","Change in mechanism of <span class='gene'>MERTK<\/span> activation in cell culture models using healthy and diseased monocytes in vitro and ex vivo","Change in mechanism of <span class='gene'>MERTK<\/span> activation in cell culture models using monocytes","Change in <span class='gene'>MERTK<\/span> signalling cascade on monocytes in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, ACLF) and in comparison to patients with acute liver failure and to healthy controls","Change in <span class='gene'>MERTK<\/span> signalling cascade on tissue macrophages in respect to innate immune function of the cells in patients with cirrhosis at different stages of disease (Child A, B, C, acute decompensation, ACLF) and in comparison to patients with acute liver failure and to healthy controls","Change in <span class='gene'>MERTK<\/span> signalling cascade on tissue macrophages","Change in <span class='gene'>MERTK<\/span> signalling cascade on monocytes","Liver Function Test (ALT, AST, AP, Albumin, Bilirubin, <span class='gene'>GGT<\/span>) at Weeks 3, 4, 8, 12, 16, 20 and 24","Cell lysis (<span class='gene'>AST<\/span>, ALT, CK18 cleaved)","Cell lysis (<span class='gene'>AST<\/span>, ALT, CK18 cleaved)","Liver: - area under the curve (AUC) <span class='gene'>GPT<\/span> (ALT) after transplantation during 7 days (minimum 1 measurement per day)","Proportion of patients with normal <span class='gene'>alanine aminotransferase<\/span>(ALT)","Impact of MARS therapy on liver regeneration assessed by serum levels of <span class='gene'>hepatocyte growth factor<\/span>.","Proinflammatory Cytokines (TNF, <span class='gene'>IL-1<\/span>, IL-6, IL-8)","Proinflammatory Cytokines (TNF, <span class='gene'>IL-1<\/span>, IL-6, IL-8)","impact of MARS therapy on liver toxins (<span class='gene'>IL-6<\/span>). Determinations in serum and in the dialysate.","Impact of MARS therapy on liver toxins (<span class='gene'>IL-6<\/span>) in serum and dialysate.","impact of MARS therapy on liver toxins (ammonia, bile acids and cytokines (<span class='gene'>IL-6<\/span> and TNF-alpha)). Determinations in serum and in the dialysate.","Proinflammatory Cytokines (TNF, IL-1, <span class='gene'>IL-6<\/span>, IL-8)","Proinflammatory Cytokines (TNF, IL-1, IL-6, <span class='gene'>IL-8<\/span>)","Proinflammatory Cytokines (TNF, <span class='gene'>IL-1<\/span>, IL-6, IL-8)","Regeneration markers (Ki-67, Fn14, <span class='gene'>CK7<\/span>)","Cell lysis (AST, ALT, <span class='gene'>CK18<\/span> cleaved)","impact of MARS therapy on liver toxins (<span class='gene'>TNF-alpha<\/span>). Determinations in serum and in the dialysate.","Impact of MARS therapy on liver toxins (<span class='gene'>TNF-alpha<\/span>) in serum and dialysate.","impact of MARS therapy on liver toxins (ammonia, bile acids and cytokines (IL-6 and <span class='gene'>TNF-alpha<\/span>)). Determinations in serum and in the dialysate.","Proinflammatory Cytokines (<span class='gene'>TNF<\/span>, IL-1, IL-6, IL-8)","Regeneration markers (Ki-67, <span class='gene'>Fn14<\/span>, CK7)","Performance of DIALIVE by assessing removal of <span class='gene'>albumin<\/span>.","To evaluate the performance of the DIALIVE device in patients with ACLF (DIALIVE arm only). Outcome measure is : - Change in <span class='gene'>Albumin<\/span> function (Human non-mercapt albumin -2 (HNA-2) / Human mercapt albumin (HMA ratio) between end of treatment with DIALIVE and the beginning of treatment with DIALIVE (Day 1)","To evaluate the performance of the DIALIVE device in patients with ACLF (DIALIVE arm only). Outcome measure is : - Change in <span class='gene'>albumin<\/span> function (Human non-mercapt albumin -2 (HNA-2) / Human mercapt albumin (HMA ratio) between end of treatment with DIALIVE and the beginning of treatment with DIALIVE (Day 1)","<span class='gene'>Albumin<\/span> time change","Levels of <span class='gene'>albumin<\/span> were measured on week0,1,2, 4,8, 12 and 24 after the start of the infusion in both groups","Outcome measure as compared between SoC and DIALIVE arm is: - Immune function: Incidence of Infection. Changes in white cell count and plasma-induced neutrophil function (Phagoburst and Phagotest), serum <span class='gene'>CRP<\/span> and cytokines (TNF-α, IL-6, IL-8, IL-10, IL1RA).","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 40 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 80 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 80 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 40 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The absolute change after treatment discontinuation from week 6 to week 10 in <span class='gene'>GGT<\/span> , compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 6 weeks in <span class='gene'>GGT<\/span>, compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 3 weeks in <span class='gene'>GGT<\/span>, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 80 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 40 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 80 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 40 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The absolute change after treatment discontinuation from week 6 to week 10 in <span class='gene'>AST<\/span> , compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 6 weeks in <span class='gene'>AST<\/span>, compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 3 weeks in <span class='gene'>AST<\/span>, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 80 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 40 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 80 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>AST<\/span> reduced to less than or equal to 40 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The absolute change after treatment discontinuation from week 6 to week 10 in <span class='gene'>AST<\/span> , compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 6 weeks in <span class='gene'>AST<\/span>, compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 3 weeks in <span class='gene'>AST<\/span>, compared between Tonka and Silymarin (Legalon)","Levels of <span class='gene'>alanine aminotransferase<\/span> were measured on week0,1,2, 4,8, 12 and 24 after the start of the infusion in both groups","<span class='gene'>Alanine aminotransferase<\/span> change","Blood leukocytes, platelets, <span class='gene'>hemoglobin<\/span> are assessed before and after each CPFA treatment","Blood leukocytes, platelets, <span class='gene'>hemoglobin<\/span> are assessed before and after each CPFA treatment","Blood leukocytes, platelets, <span class='gene'>hemoglobin<\/span> are assessed before and after each CPFA treatment","Outcome measure as compared between SoC and DIALIVE arm is: - Immune function: Incidence of Infection. Changes in white cell count and plasma-induced neutrophil function (Phagoburst and Phagotest), serum CRP and cytokines (TNF-α, IL-6, IL-8, IL-10, <span class='gene'>IL1RA<\/span>).","Outcome measure as compared between SoC and DIALIVE arm is: - Immune function: Incidence of Infection. Changes in white cell count and plasma-induced neutrophil function (Phagoburst and Phagotest), serum CRP and cytokines (TNF-α, <span class='gene'>IL-6<\/span>, IL-8, IL-10, IL1RA).","Outcome measure as compared between SoC and DIALIVE arm is: - Immune function: Incidence of Infection. Changes in white cell count and plasma-induced neutrophil function (Phagoburst and Phagotest), serum CRP and cytokines (TNF-α, IL-6, <span class='gene'>IL-8<\/span>, IL-10, IL1RA).","Outcome measure as compared between SoC and DIALIVE arm is: - Immune function: Incidence of Infection. Changes in white cell count and plasma-induced neutrophil function (Phagoburst and Phagotest), serum CRP and cytokines (TNF-α, IL-6, IL-8, <span class='gene'>IL-10<\/span>, IL1RA).","Efficacy of the DIALIVE for kidney function: changes in creatine and <span class='gene'>NGAL<\/span>","Outcome measure as compared between SoC and DIALIVE arm is: - Kidney: Changes in serum creatinine and urinary NGAL (<span class='gene'>Neutrophil gelatinase-associated lipocalin<\/span> - marker of kidney injury).","Outcome measure as compared between SoC and DIALIVE arm is: - Immune function: Incidence of Infection. Changes in white cell count and plasma-induced neutrophil function (Phagoburst and Phagotest), serum CRP and cytokines (<span class='gene'>TNF-α<\/span>, IL-6, IL-8, IL-10, IL1RA).","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 80 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 40 U/L after 3 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 80 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The percentage of patients with <span class='gene'>GGT<\/span> reduced to less than or equal to 40 U/L after 6 weeks of treatment, compared between Tonka and Silymarin (Legalon)","The absolute change after treatment discontinuation from week 6 to week 10 in <span class='gene'>GGT<\/span> , compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 6 weeks in <span class='gene'>GGT<\/span>, compared between Tonka and Silymarin (Legalon)","The absolute change from Baseline to 3 weeks in <span class='gene'>GGT<\/span>, compared between Tonka and Silymarin (Legalon)","The influence on levels of <span class='gene'>ALB<\/span>(g/L) after UC-MSC infusions","Comparison of levels of <span class='gene'>FasL<\/span> among the groups after UC-MSC infusions","Quantitative assessment of <span class='gene'>CD34<\/span> positive cells in liver biopsy samples in both groups.","Total number of <span class='gene'>CD34<\/span> positive cells in histopathological examination of bone marrow in both groups","On Immunohistochemistry of liver biopsy tissue,quantification of + ve <span class='gene'>CD34<\/span> cells will be done","Quantitative assessment of <span class='gene'>CD34<\/span> positive cells in serum in both groups.","Changes in the levels of imunoglobulins <span class='gene'>IgA<\/span>, IgG, IgM, IgD, IgE","The influence on levels of ALT (U/L) and <span class='gene'>AST<\/span> (U/L) after UC-MSC infusions","The influence on levels of ALT (U/L) and <span class='gene'>AST<\/span> (U/L) after UC-MSC infusions","Changes in the levels of imunoglobulins IgA, IgG, IgM, IgD, <span class='gene'>IgE<\/span>","Change in the levels of <span class='gene'>IL-6<\/span> and TNF alpha (Tumor Necrosis Factor) in HVPE arm from baseline till within 24-hours of the last session of High Volume Plasma Exchange.","Change in the levels of <span class='gene'>IL-6<\/span> and TNF alpha (Tumor Necrosis Factor) in control arm from baseline till 5 days.","Changes in the levels of immunomodulators - <span class='gene'>IL-6<\/span>, TNF alpha","Comparison of levels of <span class='gene'>KIR2DL1<\/span> among the groups after UC-MSC infusions","Comparison of levels of <span class='gene'>KIR2DL3<\/span> among the groups after UC-MSC infusions","Comparison of levels of <span class='gene'>KIR3DL1<\/span> among the groups after UC-MSC infusions","Comparison of levels of <span class='gene'>NKG2A<\/span> among the groups after UC-MSC infusions","urine <span class='gene'>neutrophil gelatinase-associated lipocalin<\/span> (NGAL)","urine neutrophil gelatinase-associated lipocalin (<span class='gene'>NGAL<\/span>)","urine neutrophil gelatinase-associated lipocalin (<span class='gene'>NGAL<\/span>) as a surrogate marker of renal function","urine <span class='gene'>neutrophil gelatinase-associated lipocalin<\/span> (NGAL) as a surrogate marker of renal function","Comparison of levels of <span class='gene'>perforin<\/span> among the groups after UC-MSC infusions","Change in the levels of IL-6 and TNF alpha (<span class='gene'>Tumor Necrosis Factor<\/span>) in HVPE arm from baseline till within 24-hours of the last session of High Volume Plasma Exchange.","Change in the levels of IL-6 and <span class='gene'>TNF<\/span> alpha (Tumor Necrosis Factor) in HVPE arm from baseline till within 24-hours of the last session of High Volume Plasma Exchange.","Change in the levels of IL-6 and <span class='gene'>TNF<\/span> alpha (Tumor Necrosis Factor) in control arm from baseline till 5 days.","Change in the levels of IL-6 and TNF alpha (<span class='gene'>Tumor Necrosis Factor<\/span>) in control arm from baseline till 5 days.","Changes in the levels of immunomodulators - IL-6, <span class='gene'>TNF<\/span> alpha","Endothelial function measured by <span class='gene'>von Willebrand factor<\/span> levels","<span class='gene'>von Willebrand factor<\/span>","Comparison of levels of <span class='gene'>NKP46<\/span> among the groups after UC-MSC infusions","Comparison of levels of <span class='gene'>NKG2D<\/span> among the groups after UC-MSC infusions","Efficacy 3 serum <span class='gene'>prothrombin<\/span> time","serum <span class='gene'>prothrombin<\/span> time","Defined as a modification of the Olthoff criteria: <span class='gene'>Prothrombin<\/span> time/ international normalized ratio (INR) >1.6 and or serum total bilirubin >10 mg/dL on postoperative day 7","(<span class='gene'>AST<\/span>) Aspartate Aminotransferase","serum levels of alanine aminotransferase (ALT), <span class='gene'>AST<\/span>, alkaline phosphatase (AlkP), gamma-glutamyl transferase (γGT), and total bilirubin","(<span class='gene'>AST<\/span>) Aspartate Aminotransferase","serum levels of alanine aminotransferase (ALT), <span class='gene'>AST<\/span>, alkaline phosphatase (AlkP), gamma-glutamyl transferase (γGT), and total bilirubin",". Primary endpoint is defined by postoperative liver injury assessed by peak serum value of aspartate aminotransferase (AST) or <span class='gene'>alanine aminotransferase<\/span> (ALT).",". Primary endpoint is defined by postoperative liver injury assessed by peak serum value of aspartate aminotransferase (AST) or alanine aminotransferase (<span class='gene'>ALT<\/span>).","(ALT) <span class='gene'>Alanine Aminotransferase<\/span>","serum levels of <span class='gene'>alanine aminotransferase<\/span> (ALT), AST, alkaline phosphatase (AlkP), gamma-glutamyl transferase (γGT), and total bilirubin","serum levels of alanine aminotransferase (<span class='gene'>ALT<\/span>), AST, alkaline phosphatase (AlkP), gamma-glutamyl transferase (γGT), and total bilirubin","(In selected centers) value of perfusate's alanine transaminase (<span class='gene'>ALT<\/span>)","(In selected centers) value of perfusate's <span class='gene'>alanine transaminase<\/span> (ALT)","Percentage of participants who developed Early Allograft Dysfunction (EAD) which is defined as: Aspartate Transaminase (AST) or Alanine Transaminase (<span class='gene'>ALT<\/span>)> 2,000 U/L at any point within the first seven post-transplant days, or. Total Bilirubin (TB) > 10 mg/dL on postoperative day 7,or. International Normalized Ratio (INR)> 1.6 on postoperative day 7.","Percentage of participants who developed Early Allograft Dysfunction (EAD) which is defined as: Aspartate Transaminase (AST) or <span class='gene'>Alanine Transaminase<\/span> (ALT)> 2,000 U/L at any point within the first seven post-transplant days, or. Total Bilirubin (TB) > 10 mg/dL on postoperative day 7,or. International Normalized Ratio (INR)> 1.6 on postoperative day 7.","(In selected centers) value of perfusate's <span class='gene'>high mobility group box-1<\/span> (HMBG) protein","(In selected centers) value of perfusate's high mobility group box-1 (<span class='gene'>HMBG<\/span>) protein","hepatic/renal NIRS measurements and biochemical indicators of graft function: - <span class='gene'>NGAL<\/span> for kidney transplantation - INR, SGOT/SGPT, bilirubin, lactate for liver transplantation","Changes in plasma <span class='gene'>renin<\/span> activity","(In selected centers) value of perfusate's <span class='gene'>thrombomodulin<\/span>","(In selected centers) value of perfusate's <span class='gene'>cytochrome C<\/span>","Comparison of hepatic encephalopathy score before and after two <span class='gene'>albumin<\/span> dialysis systems : with recirculation (MARS™ system) and without recirculation (SPAD™ system)","Comparison of pulsatility index of middle cerebral artery recorded by transcranial doppler before and after two <span class='gene'>albumin<\/span> dialysis system : with recirculation (MARS™ system) and without recirculation (SPAD™ system)","Comparison of tolerance of two <span class='gene'>albumin<\/span> dialysis sytems : with recirculation (MARS™ system) and without recirculation (SPAD™ system)","Comparison of total plasmatic bilirubin level before and after two <span class='gene'>albumin<\/span> dialysis systems : with recirculation (MARS™ system) and without recirculation (SPAD™ system)","Tolerance will be evaluated by effect of <span class='gene'>albumin<\/span> dialysis on coagulation indices : prothrombin time (seconds) and international normalized ratio, activated partial thromboplastin time ratio, fibrinogen level (g/L), factor V level (%), platelet count (×10(9) /L), hemoglobin level (g/L), red cell count (10(12)/L), hematocrit level (%). Coagulation indices will be measured by an arterial sample before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours.","Comparison of bile acids and conjugated bilirubin levels before and after two <span class='gene'>albumin<\/span> dialysis systems: with recirculation (MARS™ system) and without recirculation (SPAD™ system).","Plasma dipeptidyl peptidase-4 (<span class='gene'>DPP-4<\/span>) activity","Plasma <span class='gene'>dipeptidyl peptidase-4<\/span> (DPP-4) activity","Plasma <span class='gene'>DPP-4<\/span> concentration","maximum achievable pharmacologic effect (Emax), area under the concentration-time curve from 0 up to last quantifiable concentration based on <span class='gene'>EPO<\/span> concentration (AUCE,last), tmax","<span class='gene'>Erythropoietin<\/span> in plasma","The MELD score provides an objective and granular assessment of liver improvement as a continuous variable. The calculation of MELD score is based on three biochemical variables (serum bilirubin, creatinine and international normalized ratio [INR] of <span class='gene'>prothrombin<\/span> time). The MELD equation is as follows: 9.57 x ln(creatinine mg/dL) +3.78 x ln(bilirubin mg/dL) +11.2 x ln (INR) + 6.43. Scores are multiplied by 10 and rounded to the nearest whole number and range from 6 (less ill) to 40 (gravely ill). MELD scores were determined at Baseline (Day 1) and again at Week 12, Follow-up (FU) Week 12 (Week 24), and FU Week 24 (Week 36). Change from baseline in MELD score = Post-baseline MELD score - baseline MELD score.","concentration-response relationship of dabigatran assessed by analysis of activated partial thromboplastin time (aPTT), ecarin clotting time (ECT) , <span class='gene'>prothrombin<\/span> time (PT) expressed as international normalised ratio (INR), and thrombin time (TT)","Tolerance will be evaluated by effect of albumin dialysis on coagulation indices : <span class='gene'>prothrombin<\/span> time (seconds) and international normalized ratio, activated partial thromboplastin time ratio, fibrinogen level (g/L), factor V level (%), platelet count (×10(9) /L), hemoglobin level (g/L), red cell count (10(12)/L), hematocrit level (%). Coagulation indices will be measured by an arterial sample before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours.","concentration-response relationship of dabigatran assessed by analysis of activated partial <span class='gene'>thromboplastin<\/span> time (aPTT), ecarin clotting time (ECT) , prothrombin time (PT) expressed as international normalised ratio (INR), and thrombin time (TT)","Tolerance will be evaluated by effect of albumin dialysis on coagulation indices : prothrombin time (seconds) and international normalized ratio, activated partial <span class='gene'>thromboplastin<\/span> time ratio, fibrinogen level (g/L), factor V level (%), platelet count (×10(9) /L), hemoglobin level (g/L), red cell count (10(12)/L), hematocrit level (%). Coagulation indices will be measured by an arterial sample before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours.","Basic hematological parameters:~<span class='gene'>hemoglobin<\/span>, hematocrit, platelets and leukocytes.~Metabolic parameters:~Glucose, uric acid, triglycerides, cholesterol, HDL and LDL cholesterol.","Tolerance will be evaluated by effect of albumin dialysis on coagulation indices : prothrombin time (seconds) and international normalized ratio, activated partial thromboplastin time ratio, fibrinogen level (g/L), factor V level (%), platelet count (×10(9) /L), <span class='gene'>hemoglobin<\/span> level (g/L), red cell count (10(12)/L), hematocrit level (%). Coagulation indices will be measured by an arterial sample before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours.","Basic hematological parameters:~<span class='gene'>hemoglobin<\/span>, hematocrit, platelets and leukocytes.~Metabolic parameters:~Glucose, uric acid, triglycerides, cholesterol, HDL and LDL cholesterol.","Tolerance will be evaluated by effect of albumin dialysis on coagulation indices : prothrombin time (seconds) and international normalized ratio, activated partial thromboplastin time ratio, fibrinogen level (g/L), factor V level (%), platelet count (×10(9) /L), <span class='gene'>hemoglobin<\/span> level (g/L), red cell count (10(12)/L), hematocrit level (%). Coagulation indices will be measured by an arterial sample before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours.","Basic hematological parameters:~<span class='gene'>hemoglobin<\/span>, hematocrit, platelets and leukocytes.~Metabolic parameters:~Glucose, uric acid, triglycerides, cholesterol, HDL and LDL cholesterol.","Tolerance will be evaluated by effect of albumin dialysis on coagulation indices : prothrombin time (seconds) and international normalized ratio, activated partial thromboplastin time ratio, fibrinogen level (g/L), factor V level (%), platelet count (×10(9) /L), <span class='gene'>hemoglobin<\/span> level (g/L), red cell count (10(12)/L), hematocrit level (%). Coagulation indices will be measured by an arterial sample before and at the end of MARS™ dialysis (8 hours) and before and at the end of SPAD™ dialysis (10 hours) ; the two variations will be compared. Each patient will receive the two dialysis systems separated by a free interval that will last between 12 and 48 hours.","Area under the concentration-time curve from 0 to 24 hours of pegylated interferon (Peg <span class='gene'>IFN<\/span>) in the plasma (AUC0-24h)","maximum achievable pharmacologic effect (Emax), area under the concentration-time curve from 0 up to last quantifiable concentration based on <span class='gene'>EPO<\/span> concentration (AUCE,last), tmax","Concentration of <span class='gene'>Caspase 3<\/span>/7 Relative Light Units","Levels of <span class='gene'>Caspase 3<\/span>/7 RLU","Liver function tests, complete blood count and coagulation tests were performed within the first 24h after admission. The liver function tests included alanine aminotranferase, aspartate aminotranferase, total bilirubin (TBil), albumin, serum sodium, alpha-fetoprotein (AFP) and creatinine. Complete blood count was made up of platelet and <span class='gene'>hemoglobin<\/span> (Hb). Coagulation tests contained prothrombin activity (PTA) and international normalized ratio (INR). Additionally, hepatitis B e antigen (HBeAg) was detected by conventional serological assays. Serum HBV DNA was measured by quantitative polymerase chain reaction(PCR) assay (Roche Amplicor, limit of detectability of 100 IU/ml) after admission.","Liver function tests, complete blood count and coagulation tests were performed within the first 24h after admission. The liver function tests included alanine aminotranferase, aspartate aminotranferase, total bilirubin (TBil), albumin, serum sodium, alpha-fetoprotein (AFP) and creatinine. Complete blood count was made up of platelet and <span class='gene'>hemoglobin<\/span> (Hb). Coagulation tests contained prothrombin activity (PTA) and international normalized ratio (INR). Additionally, hepatitis B e antigen (HBeAg) was detected by conventional serological assays. Serum HBV DNA was measured by quantitative polymerase chain reaction(PCR) assay (Roche Amplicor, limit of detectability of 100 IU/ml) after admission.","Liver function tests, complete blood count and coagulation tests were performed within the first 24h after admission. The liver function tests included alanine aminotranferase, aspartate aminotranferase, total bilirubin (TBil), albumin, serum sodium, alpha-fetoprotein (AFP) and creatinine. Complete blood count was made up of platelet and <span class='gene'>hemoglobin<\/span> (Hb). Coagulation tests contained prothrombin activity (PTA) and international normalized ratio (INR). Additionally, hepatitis B e antigen (HBeAg) was detected by conventional serological assays. Serum HBV DNA was measured by quantitative polymerase chain reaction(PCR) assay (Roche Amplicor, limit of detectability of 100 IU/ml) after admission.","Levels of <span class='gene'>CK18<\/span>/M30","Levels of <span class='gene'>CK18<\/span>/M65","Caspase-cleaved cytokeratin serum levels (<span class='gene'>CK18<\/span>/M30)","Caspase full-length cytokeratin serum levels <span class='gene'>CK18<\/span>/M65","Improve biochemical indexes [alanine aminotransferase (ALT), <span class='gene'>albumin<\/span> (ALB), total bilirubin (TBIL), prothrombin time (PT), INR and so on]","Improve biochemical indexes [alanine aminotransferase (ALT), <span class='gene'>ALB<\/span>umin (ALB), total bilirubin (TBIL), prothrombin time (PT), INR and so on]","Improve biochemical indexes [alanine aminotransferase (ALT), albumin (ALB), total bilirubin (TBIL), <span class='gene'>prothrombin<\/span> time (PT), INR and so on]","The primary endpoint of the study is the modulation of the IR injury made by NAC and/or MET in patients undergoing liver surgery. For this purpose a decrease of 100 UI/L of <span class='gene'>AST<\/span> and ALT is expected compared with placebo.","A decrease of 100 UI/L of <span class='gene'>AST<\/span> and ALT compared with placebo.","The primary endpoint of the study is the modulation of the IR injury made by NAC and/or MET in patients undergoing liver surgery. For this purpose a decrease of 100 UI/L of <span class='gene'>AST<\/span> and ALT is expected compared with placebo.","A decrease of 100 UI/L of <span class='gene'>AST<\/span> and ALT compared with placebo.","Improve biochemical indexes [alanine aminotransferase (<span class='gene'>ALT<\/span>), albumin (ALB), total bilirubin (TBIL), prothrombin time (PT), INR and so on]","Improve biochemical indexes [<span class='gene'>alanine aminotransferase<\/span> (ALT), albumin (ALB), total bilirubin (TBIL), prothrombin time (PT), INR and so on]","• Mobilization of <span class='gene'>CD34<\/span> cells in the peripheral blood, a surrogate marker for hematopoietic stem cell mobilization","Transplant free survival at 6 months, histo-pathological evidence of hepatic regeneration and mobilization of <span class='gene'>CD34<\/span>/stem cells, improvement in severity assessment indices","Rate of change of <span class='gene'>Prothrombin<\/span> Rate initiation","Liver Transplantation: bilirubin, INR, transaminases, <span class='gene'>GGT<\/span>, at day 7, months 1, 3, 6, 9, 12. Kidney Transplanttaion: number of post transplant hemodialysis, creatinine at day 7, months 1, 3, 6, 9, 12.","Liver Transplantation: bilirubin, INR, transaminases, <span class='gene'>GGT<\/span>, at day 7, months 1, 3, 6, 9, 12. Kidney Transplanttaion: number of post transplant hemodialysis, creatinine at day 7, months 1, 3, 6, 9, 12.","The level of alpha-fetoprotein (<span class='gene'>AFP<\/span>)","The level of <span class='gene'>alpha-fetoprotein<\/span> (AFP)","<span class='gene'>Albumin<\/span> functional capacity","Ischemia-modified <span class='gene'>albumin<\/span>","<span class='gene'>Albumin<\/span> binding capacity","Conventional hepatic function parameters: aspartate transaminase, alanine transaminase, gamma-glutamyl transferase, alkaline phosphatase, total, conjugated and not conjugated serum bilirubin, <span class='gene'>serum albumin<\/span>, international normalized ratio (INR) and prothrombin index","The levels of serum Total Protein and <span class='gene'>Albumin<\/span>","The levels of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and <span class='gene'>Cholinesterase<\/span> (CHE)","The levels of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Cholinesterase (<span class='gene'>CHE<\/span>)","Conventional hepatic function parameters: aspartate transaminase, alanine transaminase, gamma-glutamyl transferase, alkaline phosphatase, total, conjugated and not conjugated serum bilirubin, serum albumin, international normalized ratio (INR) and <span class='gene'>prothrombin<\/span> index","The levels of <span class='gene'>Prothrombin<\/span> Activity (PA) and Prothrombin Time (PT)","Conventional hepatic function parameters: aspartate transaminase, <span class='gene'>alanine transaminase<\/span>, gamma-glutamyl transferase, alkaline phosphatase, total, conjugated and not conjugated serum bilirubin, serum albumin, international normalized ratio (INR) and prothrombin index","The levels of serum Alanine Aminotransferase (<span class='gene'>ALT<\/span>), Aspartate Aminotransferase (AST) and Cholinesterase (CHE)","The levels of serum <span class='gene'>Alanine Aminotransferase<\/span> (ALT), Aspartate Aminotransferase (AST) and Cholinesterase (CHE)","Plasma <span class='gene'>renin<\/span> activity","Assessment of the efficacy of human fetal liver progenitor cell transplantation on Child-Pugh score. The Child-Pugh (CP) classification is a scoring system used for the classification of the severity of cirrhosis. It includes three continuous variables (bilirubin, <span class='gene'>albumin<\/span> and INR) and two discrete variables (ascites and encephalopathy). Each variable is scored 1-3 with 3 indicating most severe derangement. The determination of CP score may range from 5 to 15 and the final score allows to categorize patients in Child-Pugh A (5-6 points), B (7-9 points) and C (10-15 points). The highest is the score the sickest is the patient.","mobilization of <span class='gene'>CD34<\/span> cells in the peripheral blood","Assessment of the efficacy of human fetal liver progenitor cell transplantation on Meld score. The Model for End-stage Liver Disease (MELD) scoring system aims at stratifying recipients by their disease severity according to a score estimating the 3-month probability of death on the waiting list. The calculation of an individual's MELD score is based on three objective lab parameters (bilirubin, serum creatinine and <span class='gene'>prothrombin<\/span> time expressed as international normalized ratio, INR) and it includes logarithmic transformations and multiplication by several factors. It ranges between 6 and 40. The highest is the score the lower is the patient's survival.","Rate of <span class='gene'>albumin<\/span> synthesis","<span class='gene'>Transthyretin<\/span> synthesis, fibrinogen synthesis, whole body glucose and protein kinetics","Renal function, serum bilirubin, bile acids, <span class='gene'>prothrombin<\/span> activity and the hemodynamics of patients with Hepatic Encephalopathy","- TNF alpha and <span class='gene'>IL6<\/span> plasma concentration before, at 2 months and at 6 months as predictive factor of mortality","- <span class='gene'>TNF<\/span> alpha and IL6 plasma concentration before, at 2 months and at 6 months as predictive factor of mortality"],[2021,2021,2021,2021,2021,2021,2021,2021,2021,2021,2021,2021,2020,2020,2020,2020,2020,2020,2020,2020,2020,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2019,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2018,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2017,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2016,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2015,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2014,2013,2013,2013,2013,2013,2013,2013,2013,2013,2012,2012,2012,2012,2012,2012,2012,2012,2012,2011,2011,2011,2011,2011,2010,2010,2010,2010,2010,2010,2010,2010,2010,2010,2010,2010,2010,2010,2010,2009,2009,2009,2008,2008,2006,2005,2005]],"container":"<table class=\"display\">\n  <thead>\n    <tr>\n      <th>nct_id<\/th>\n      <th>Symbol<\/th>\n      <th>biomarker<\/th>\n      <th>measurement<\/th>\n      <th>year<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"pageLength":10,"columnDefs":[{"className":"dt-right","targets":4}],"order":[],"autoWidth":false,"orderClasses":false,"orderCellsTop":true}},"evals":[],"jsHooks":[]}</script>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
